Celyad SA said it will pay $12.5 million in cash and issue $12.5 million worth of its shares for a greater share of the future revenues generated by certain CAR-T cell therapies for the treatment of cancer.
Celyad had obtained access to the assets after the acquisition of OnCyte LLC from privately held Celdara Medical LLC in 2015. The assets were developed using technology licensed from the Dartmouth College.
Celyad will make the payment to Celdara Medical LLC and Dartmouth College. The development reflects increased confidence in the future potential of the assets, including CYAD-01.
Celyad said it will use the money received from Novartis AG to partially cover the cash portion of the agreement.